Home

The need for high safer and more potent therapies for cancer patients led Himalaya to the Conditionally Active Biologics (CAB) technology. CAB antibodies are innovative, differentiated therapeutics. They are selective and bind reversibly only to targets on tumor cells, and not on normal cells, thereby widening the therapeutic window. In non-human primate and patient studies to date, CAB antibodies have demonstrated high safety with higher potency.